Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells 14,609 Shares

Posted by Francis Steltz on Jul 2nd, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE – Get Free Report) CMO Harold Bernstein sold 14,609 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $29.90, for a total value of $436,809.10. Following the sale, the chief marketing officer directly owned 14,609 shares of the company’s stock, valued at approximately $436,809.10. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harold Bernstein also recently made the following trade(s):

On Thursday, May 14th, Harold Bernstein sold 15,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.22, for a total value of $393,300.00.

Maze Therapeutics Stock Performance

Shares of Maze Therapeutics stock traded up $1.45 during trading hours on Thursday, hitting $31.26. 575,498 shares of the company were exchanged, compared to its average volume of 717,789. Maze Therapeutics, Inc. has a 1 year low of $10.98 and a 1 year high of $53.65. The company has a current ratio of 17.88, a quick ratio of 17.88 and a debt-to-equity ratio of 0.11. The business has a 50-day moving average of $25.81 and a 200-day moving average of $35.73. The stock has a market capitalization of $1.73 billion, a price-to-earnings ratio of -12.36 and a beta of 2.14.

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). The company had revenue of $20.00 million for the quarter. As a group, analysts expect that Maze Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Institutional Trading of Maze Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Seven Fleet Capital Management LP purchased a new stake in Maze Therapeutics during the first quarter worth $917,000. Bank of America Corp DE raised its stake in shares of Maze Therapeutics by 961.3% during the 1st quarter. Bank of America Corp DE now owns 195,084 shares of the company’s stock worth $5,823,000 after buying an additional 176,703 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Maze Therapeutics by 214.1% during the 1st quarter. Royal Bank of Canada now owns 2,029 shares of the company’s stock worth $61,000 after buying an additional 1,383 shares during the last quarter. Exome Asset Management LLC purchased a new stake in shares of Maze Therapeutics in the 1st quarter worth about $2,642,000. Finally, The Manufacturers Life Insurance Company grew its stake in Maze Therapeutics by 111.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 14,570 shares of the company’s stock valued at $435,000 after acquiring an additional 7,673 shares during the last quarter.

Analysts Set New Price Targets

MAZE has been the subject of a number of recent analyst reports. Wedbush raised their price objective on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research report on Monday, March 16th. HC Wainwright increased their target price on Maze Therapeutics from $60.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th. Wall Street Zen raised Maze Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Truist Financial decreased their price target on Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 14th. Finally, BTIG Research reaffirmed a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a report on Wednesday, March 25th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $66.00.

Check Out Our Latest Stock Analysis on Maze Therapeutics

Maze Therapeutics Company Profile

(Get Free Report)

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.